A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Inclusion Criteria:

• Age ≥ 12 to < 18 years at day 1.

• Participant has a diagnosis of AD (according to American Academy of DermatologyConsensus Criteria [Eichenfield, 2014]) that has been present for at least 12 monthsbefore signing of informed consent

• Prior to informed consent, history of inadequate response to topical corticosteroids (TCS) of medium to higher potency (with or without topical calcineurin inhibitors [TCI] as appropriate) or for whom topical treatments are otherwise medicallyinadvisable (eg, because of important side effects or safety risks)

• Eczema Area and Severity Index (EASI) score ≥ 12

• vIGA-AD score ≥ 3

• ≥ 10% BSA of AD involvement at day 1 pre-enrollment

Exclusion Criteria:

• Treatment with a biological product within 12 weeks or 5 half-lives, whichever islonger, prior to Day 1

• Treatment with any of the following medications or therapies within 4 weeks or 5half-lives, whichever is longer, prior to Day 1:

• Systemic corticosteroids

• Systemic immunosuppressants

• Phototherapy

• Oral or topical janus kinase inhibitors

• Treatment with any of the following agents within 1 week before day 1pre-enrollment:

• Topical PDE4 inhibitors

• Other topical immunosuppressive agents (not including TCS/TCI)

• Combination topical agents containing a high- or super-high potencycorticosteroid